Flumazenil 78755-81-4

.cp_wz table {border-top: 1px solid #ccc;border-left:1px solid #ccc; } .cp_wz table td{border-right: 1px solid #ccc; border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;} .cp_wz table th {border-right: 1px solid #ccc;border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;}


Molecular Weight:

303.29 Flumazenil is a competitive GABAA receptor antagonist, used in the treatment of benzodiazepine overdoses.

Biological Activity

Flumazenil interacts at the central benzodiazepine receptor to
antagonize or reverse the behavioral, neurologic, and electrophysiologic
effects of benzodiazepine agonists and inverse agonists. Flumazenil is
of some benefit in hepatic encephalopathy, but until well-designed
clinical trials are conducted, hepatic encephalopathy must be considered
an investigational indication for flumazenil.





Flumazenil (10 mg/kg) effectively prevents the reduction produced by allopregnanolone in rats. Flumazenil (5-20 mg/kg) antagonizes the anticonvulsant and adverse
effects of diazepam but not GYKI 52466 in mice. Flumazenil slightly
reduces the anticonvulsant activity of NBQX in the MES model but not in
the PTZ test. Flumazenil (3.0 mg/kg) blocks the changes
withdrawal from chronic ethanol treatment, which leads to a decrease in
open arm time and percent open arm entries.

Contact us if you need more details on 78755-81-4. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Flumazenil 78755-81-4、78755-81-4 Flumazenil. If these products fail to match your need, please contact us and we would like to provide relevant information.

Product Categories : Transmembrane Transporters > GABA Receptor Inhibitor